Effect of oral L-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients

Annals of Nutrition and Metabolism

Volumn 52, Issue 4, 2008, Pages 335-338

  González Ortiz, Manuel ^a   Hernández González, Sandra O ^a   Hernández Salazar, Eduardo ^a   Martínez Abundis, Esperanza ^a  

^a NONE

Author keywords

Insulin sensitivity; L carnitine; Lipid profile; Type 2 diabetes

Indexed keywords

CARNITINE; INSULIN; ISOPHANE INSULIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; HUMAN; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CARNITINE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; LIPIDS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; VITAMIN B COMPLEX;

EID: 49549121822     PISSN: 02506807     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151488     Document Type: Article

References (16)

1. Zachary T, Bloomgarden MD: Insulin resistance concepts. Diabetes Care 2007;30:1320-1325.
2. Miles J, Jensen M: Counterpoint: visceral adiposity is not causally related to insulin resistance. Diabetes Care 2005;28:2326-2328.
3. Lamhonwah A: Human high-affinity carnitine transporter OCTN2 protein: subcellular localization and functional restoration of carnitine uptake in mutant cell lines with the carnitine transporter defect. Biochem Biophys Res Commun 1999;264:909-914.
4. Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, Gasbarrini G: L-Carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr 1999;18:77-82.
5. Capaldo B, Napoli R, Di Bonito P, Saccà L: Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1991;14:191-195.
6. Jeyaseelan L, Rao PS: Methods of determining sample sizes in clinical trials. Indian Pediatr 1989;26:115-121.
7. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23:295-301.
8. Albareda I, Rodríguez-Espinosa J, Murugo M, de Leiva A, Corcoy R: Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state during an oral glucose tolerance test. Diabetologia 2000;43:1507-1511.
9. Gregory S: Insulin resistance: lifestyle and nutritional interventions. Altern Med Rev 2000;2:109-132.
10. Krebs M, Roden M: Nutrient-induced insulin resistance in human skeletal muscle. Curr Med Chem 2004;11:901-908.
11. Mingrone G: Carnitine in type 2 diabetes. Ann NY Acad Sci 2004;1033:99-107.
12. Ferrannini E, Buzzigoli G, Bevilacqua S, et al: Interaction of carnitine with insulin-stimulated glucose metabolism in humans. Am J Physiol 1988;255:E946-E952.
13. De Gaetano A, Mingrone G, Castagneto M, Calvani M: Carnitine increases glucose disposal in humans. J Am Coll Nutr 1999;18:289-295.
14. Godárová A, Litzlbauer E, Brunner S, Agu AC, Lohninger A, Hofbauer R: L-Carnitine regulates mRNA expression levels of the carnitine acyltransferases - CPT1A, CPT2 and CRAT. Monatshefte Chemie/Chem Monthly 2005;136:1349-1363.
15. Rahbar AR, Shakerhosseini R, Saadat N, Taleban F, Pordal A, Gollestan B: Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus. Eur J Clin Nutr 2005;59:592-596.
16. Karlic H, Lohninger A, Laschan C, Lapin A, Böhmer F, Huemer M, Guthann E, Rappold E, Pfeilstöcker M: Downregulation of carnitine acyltransferases and organic cation transporter OCTN2 in mononuclear cells in healthy elderly and patients with myelodysplastic syndromes. J Mol Med 2003;81:435-442.